SCHEMBL893041

SCHEMBL893041

NC(=O)c1cc2cc(Cl)c(O)cc2oc1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.61
ALDH1A1 P00352 4/20 0.51
LMNA P02545 3/20 0.51
GPR35 Q9HC97 7/20 0.50
POLB P06746 1/20 0.49
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 2/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAOB P27338 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
RXFP1 Q9HBX9 2/20 0.44
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30644916 1.00 KDM4E (0.61) KDM4EALDH1A1LMNAGPR35POLB
SCHEMBL530998 0.86 GPR35 (0.68) KDM4EALDH1A1GPR35POLBHPGD
SCHEMBL14405907 0.86 MAOB (0.60) KDM4EALDH1A1LMNAGPR35MAPT
SCHEMBL13494165 0.85 MAOB (0.58) KDM4EALDH1A1GPR35MAPTMEN1
SCHEMBL13494158 0.84 MAOB (0.61) KDM4EALDH1A1LMNAGPR35MAPT
SCHEMBL15084990 0.81 TSHR (0.49) KDM4EALDH1A1LMNAGPR35MAOB
SCHEMBL13494164 0.81 KDM4E (0.57) KDM4EALDH1A1GPR35MEN1HPGD
SCHEMBL14405916 0.80 KDM4E (0.54) KDM4EALDH1A1GPR35HPGDMAOB
SCHEMBL15082533 0.79 TSHR (0.66) KDM4EALDH1A1LMNAGPR35MEN1
SCHEMBL1406180 0.77 MAOB (0.64) KDM4EALDH1A1MAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12372526-B2 Method for identifying modulators of G3BP activity ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2025-07-29 US claimed
US-20220091120-A1 METHOD FOR IDENTIFYING MODULATORS OF G3BP ACTIVITY ST. JUDE CHILDREN'S RESEARCH HOSPITAL 2022-03-24 US claimed
US-8487078-B2 Kinase and phosphatase assays Life Technologies Corporation (US) 2013-07-16 US claimed
US-8409814-B2 Sensor proteins and assay methods Life Technologies Corporation (US) 2013-04-02 US claimed
EP-2192192-B1 Kinase and phosphatase assays LIFE TECHNOLOGIES CORP (US) 2012-10-03 EP claimed
US-20120083427-A1 KINASE AND PHOSPHATASE ASSAYS Life Technologies Corporation (US) 2012-04-05 US claimed
US-8067536-B2 Kinase and phosphatase assays Life Technologies Corporation (US) 2011-11-29 US claimed
US-20110111422-A1 SENSOR PROTEINS AND ASSAY METHODS Life Technologies Corporation (US) 2011-05-12 US claimed
US-20100240080-A1 KINASE AND PHOSPHATASE ASSAYS Life Technologies Corporation (US) 2010-09-23 US claimed
EP-2192192-A1 Kinase and phosphatase assays Life Technologies Corporation (US) 2010-06-02 EP claimed
US-20080213811-A1 SENSOR PROTEINS AND ASSAY METHODS INVITROGEN CORPORATION (US) 2008-09-04 US claimed
EP-1664332-A4 KINASE AND PHOSPHATASE ASSAYS INVITROGEN CORP (US) 2008-05-14 EP claimed
US-20070059787-A1 Kinase and phosphatase assays INVITROGEN CORPORATION (US) 2007-03-15 US claimed
EP-1671128-A2 MULTIPLEX BINDING AND ACTIVITY ASSAYS INVITROGEN CORPORATION (US) 2006-06-21 EP claimed
EP-1664332-A2 KINASE AND PHOSPHATASE ASSAYS INVITROGEN CORPORATION (US) 2006-06-07 EP claimed
US-20050170442-A1 Bimolecular optical probes Life Technologies Corporation 2005-08-04 US claimed
WO-2005026730-A2 MULTIPLEX BINDING AND ACTIVITY ASSAYS INVITROGEN CORPORATION (US) 2005-03-24 WO claimed
US-20050064485-A1 Multiplex binding and activity assays Life Technologies Corporation 2005-03-24 US claimed
US-20050054573-A1 Kinase and phosphatase assays Life Technologies Corporation 2005-03-10 US claimed
WO-2005012329-A2 KINASE AND PHOSPHATASE ASSAYS INVITROGEN CORPORATION (US) 2005-02-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054573-A1 Kinase and phosphatase assays PACSIN2, PNKP, ACP1 KDM4E 2000/4885ALDH1A1 4741/4885LMNA 1952/4885
US-20120083427-A1 KINASE AND PHOSPHATASE ASSAYS PTMS, ACP1, PPME1 KDM4E 1271/4885ALDH1A1 4743/4885LMNA 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.